Overview

Current studies have found the efficacy of RDN in the treatment of hypertension, however, the safety of RDN in renal function is still lacking. Therefore, the investigators are aimed to study the effect of RDN on renal function.

Eligibility

Inclusion Criteria:

        1.18<age≤75 years; 2.clinic blood pressure ≥ 140/90 mmHg or 24-hour ambulatory blood
        pressure monitoring average blood pressure ≥ 135/85 mmHg after taking 3 or more
        antihypertensive drugs for more than 4 weeks; 3.essential hypertension, renal parenchymal
        hypertension, or hypertension patients who are willing to receive RDN ; 4.who signed
        informed consent and were approved by the Ethics Committee of the First Affiliated Hospital
        of Xiamen University.
        Exclusion Criteria:
          -  pregnant women or lactating patients;
               -  identified secondary hypertension or Pseudo hypertension;
                    -  whose renal arteries were unsuitable for ablation
                         -  obvious bleeding tendency and blood system diseases;
                              -  malignant tumors or end-stage diseases; ⑥Severe peripheral
                                 vascular disease, abdominal aortic aneurysm; ⑦A history of the
                                 acute coronary syndrome within two weeks; ⑧acute or severe
                                 systemic infection; ⑨drug or alcohol dependence or refusal to sign
                                 informed consent.